Cargando…
Multicentric analytical comparability study of programmed death-ligand 1 expression on tumor-infiltrating immune cells and tumor cells in urothelial bladder cancer using four clinically developed immunohistochemistry assays
Programmed death-ligand 1 (PD-L1) expression on tumor cells (TC) or tumor-infiltrating immune cells (IC) correlated in several studies with PD-L1/programmed death-1 (PD-1) checkpoint inhibitor efficacy. Since June 2018, a positive PD-L1 status is required for atezolizumab or pembrolizumab treatment...
Autores principales: | Schwamborn, Kristina, Ammann, Johannes U, Knüchel, Ruth, Hartmann, Arndt, Baretton, Gustavo, Lasitschka, Felix, Schirmacher, Peter, Braunschweig, Till, Tauber, Robert, Erlmeier, Franziska, Hieke-Schulz, Stefanie, Weichert, Wilko |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861354/ https://www.ncbi.nlm.nih.gov/pubmed/31267201 http://dx.doi.org/10.1007/s00428-019-02610-z |
Ejemplares similares
-
Growth Arrest-Specific 6 in Chromophobe Renal Cell Carcinoma
por: Mikuteit, Marie, et al.
Publicado: (2022) -
Immunohistochemical expression of the hepatocyte growth factor in chromophobe renal cell carcinoma
por: Erlmeier, Maximilian, et al.
Publicado: (2023) -
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy
por: Eckstein, Markus, et al.
Publicado: (2018) -
Mass Spectrometry Imaging Differentiates Chromophobe Renal Cell Carcinoma and Renal Oncocytoma with High Accuracy
por: Kriegsmann, Mark, et al.
Publicado: (2020) -
Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines
por: Kneissl, Julia, et al.
Publicado: (2016)